[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341154-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-341154-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","translational-therapeutics-targeting-galectin-3-illuminates-its-contributions-to-the-pathology-of-uterine-serous-carcinoma","Translational Therapeutics - Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma","","Uterine serous cancer (USC) is a rare but highly lethal endometrial cancer subtype, and its aggressive pathology remains incompletely explained. This study examines how Galectin 3 (Gal3) expression relates to prognosis and tumor progression in USC using TCGA analyses and clinical-pathological correlations. CRISPR/Cas9-mediated Gal3 knockout and the Gal3 inhibitor GB1107 are used to test effects on USC cell proliferation, stemness, adhesion, migration, invasion, and microenvironmental remodeling, including fibroblast transitions and vascular formation. Reduced Gal3 activity predicts improved outcomes in vivo and in patient-derived organoid growth assays, supporting Gal3 inhibition as a potential therapeutic strategy.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/translational-therapeutics-targeting-galectin-3-illuminates-its-contributions-to-the-pathology-of-uterine-serous-carcinoma/341154/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/translational-therapeutics-targeting-galectin-3-illuminates-its-contributions-to-the-pathology-of-uterine-serous-carcinoma/341154.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What experimental approaches were used to test Gal3 function in USC?","Question",{"text":63,"@type":64},"Gal3 loss was modeled using CRISPR/Cas9-mediated Gal3 knockout, and Gal3 activity was inhibited using GB1107. Effects on cell proliferation and multiple malignant behaviors were then measured in USC lines and further validated in xenograft and organoid models.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},341154,1790173550,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":104,"slug":105},30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nARTICLE OPEN   \nTranslational Therapeutics  \nTargeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma  \nYusuke Matoba 1,2,3, Dominique T. Zarrella1, Venkatesh Pooladanda 1,2, Maryam Azimi Mohammadabadi 1,2, Eugene Kim 1, Shaan Kumar1, Mengyao Xu1, Xingping Qin4, Lauren J Ray5, Kyle M. Devins5, Raj Kumar1, Artem Kononenko 1, Eric Eisenhauer2,6, Irva E. Veillard 1, Wataru Yamagami3, Sarah J. Hill 2,7, Kristopher A. Sarosiek 4, Oladapo O. Yeku 1,2,8,9, David R. Spriggs 1,2,8,9 and Bo R. Rueda 1,2,6 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | BACKGROUND: Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% of uterine cancer deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features in some malignancies. However, Gal3’s role in promoting USC pathology is lacking.\u003Cbr>METHODS: We explored the relationship between LGALS3 levels and prognosis in USC patients using TCGA database, and examined the association between Gal3 levels in primary USC tumors and clinical-pathological features. CRISPR/Cas9-mediated Gal3-knockout (KO) and GB1107, inhibitor of Gal3, were employed to evaluate Gal3’s impact on cell function.\u003Cbr>RESULTS: TCGA analysis revealed a worse prognosis for USC patients with high LGALS3 . Patients with no-to-low Gal3 expression in primary tumors exhibited reduced clinical-pathological tumor progression. Gal3-KO and GB1107 reduced cell proliferation, stemness, adhesion, migration, and or invasion properties of USC lines. Furthermore, Gal3-positive conditioned media (CM) stimulated vascular tubal formation and branching and transition of ﬁbroblast to cancer-associated ﬁbroblast compared to Gal3-negative CM. Xenograft models emphasized the signiﬁcance of Gal3 loss with fewer and smaller tumors compared to controls. Moreover, GB1107 impeded the growth of USC patient-derived organoids |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| .\u003Cbr>CONCLUSION: These ﬁndings suggest inhibiting Gal3 may beneﬁt USC patients. |  |  |\n|  | British Journal of Cancer (2024) 130:1463–1476; [https://doi.org/10.1038/s41416-024-02621-x](https://doi.org/10.1038/s41416-024-02621-x) |  |\n|  |  |  |\n\nINTRODUCTION  \nEndometrial cancer is the most common cancer of the female reproductive organs. It was estimated there would be roughly 66,200 new cases reported annually in the United States in 2022 [1] . Eighty-ﬁve percent of endometrial cancers are histologically endometrioid carcinoma. However, uterine serous carcinoma (USC), which accounts for about 5-10% of all uterine cancers, has a poor prognosis [2, 3] . USC has a high rate of metastatic lesions, even when the primary lesion is contained locally (i.e., in a polyp) . Patients with USC have a higher risk of recurrence and shorter overall survival than endometrioid carcinoma at the same stage. While fewer in total number, USC accounts for about 40% of all cancer deaths from uterine cancer [2] . While white women experience a higher incidence of endometrial cancer overall, mortality disproportionally affects black women [4] . It has been reported that USC accounts for 30% of all endometrial cancer in  \nblack women [5] and may contribute to the increase in endometrial cancer deaths among them [6, 7] . Unfortunately, despite adjuvant therapy, patients with USC develop systemic relapses [8] . Overcoming this aggressive tumor histology is an urgent clinical issue. This can only be done by better deﬁning the factors and their mechanisms contributing to their aggressive nature.  \nA family of glycan recognition proteins called galectins have been reported to be involved in cancer progression and metastasis [9] . Galectins are a family of endog","cbCaih5EmE0FalkU","https://ap.wps.com/l/cbCaih5EmE0FalkU","pdf",6645318,14,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What experimental approaches were used to test Gal3 function in USC?\",\"answer\":\"Gal3 loss was modeled using CRISPR/Cas9-mediated Gal3 knockout, and Gal3 activity was inhibited using GB1107. Effects on cell proliferation and multiple malignant behaviors were then measured in USC lines and further validated in xenograft and organoid models.\"}]","Translational Therapeutics - Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma | PDF",1790040579,35,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/391e8addc350a8c660d396aa7ddbdce8.webp",983,1305,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46510928aef1dee9528d2e6588d36d18.webp",982,1304,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/438a0568de5fecc17b51a490eea2652f.webp",981,1303,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a2f51fed43f82e6592bf7909a65e6ed.webp",980,1301]